Table 1 Demographic, clinical characteristics and composite evaluation in NMOSD and HC

Age (years), mean [SD] (range)

41 [13.8] (18–69)

37.8 [12.5] (20–60)

0.50

Sex (F), N (%)

50 (79.4%)

47 (74.6%)

0.67

BMI, mean [SD] (range)

22.7 [4.0] (12.6–35.4)

22.7 [4.1] (17.1–39.0)

0.59

Antibody in serum

 AQP4 seropositivity, N(%)

55 (87.3%)

 MOG seropositivity, N(%)

4 (6.3%)

 Negative

4 (6.3%)

Number of attacks, mean [SD] (range)

3.7 [3.9] (1–21)

Disease duration (year), mean [SD] (range)

4.2 [4.3] (0.25–20)

EDSS, mean [SD] (range)

3.1 [1.9] (0–7.5)

Clinical phenotype, N(%)

 ON

15 (23.8%)

 TM

22 (34.9%)

 ON + TM

26 (41.3%)

Segments of MR lesions, mean [SD] (range)

 Cervical cord lesions

2.2 [2.2] (0–7)

 Thoracic cord lesions

2.2 [3.4] (0–12)

 Total number of spinal cord lesion

4.3 [4.3] (0–17)

Therapy, N(%)

 MMF

37 (58.7%)

 AZA

5 (7.9%)

 RTX

17 (30.0%)

 periodic IVIG

1 (1.6%)

 only low-dose prednisolone

3 (4.8%)

COMPASS-31, mean [SD] (range)

17.2 [10.3] (1–43)

11.6 [7.3] (0–32)

0.002

 Orthostatic intolerance

1.8 [2.3] (0–10)

1.1 [1.9] (0–6)

0.003

 Vasomotor

0.8 [1.7] (0–6)

0.2 [0.8] (0–5)

0.007

 Secretomotor

2.1 [1.7] (0–6)

1.3 [1.4] (0–6)

0.006

 Gastrointestinal

6.2 [4.0] (0–15)

5.2 [3.8] (0–16)

0.18

 Bladder

1.4 [1.7] (0–6)

0.4 [0.9] (0–4)

 < 0.001

 Pupillomotor

4.7 [3.5] (0–14)

3.4 [2.9] (0–10)

0.04